Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients

NCT07164950 · tracked via the Priya Life Science China tracker

Sponsor

Sheng Zhang

Phase

Not applicable

Started

2025-08-30

Last updated

2025-09-15

Condition(s) studied

Urothelial CarcinomaAdvanced Solid TumorsChemotherapy-Induced Peripheral NeuropathyAntibody-drug Conjugates

Investigational drug(s) / intervention(s)

Medical-grade compression stocking

Medical-grade compression stocking: A knee-high compression stocking providing 20-30 mmHg pressure will be applied to the assigned foot during the ADC treatment period to prevent chemotherapy-induced peripheral neuropathy (CIPN). Stockings will be worn daily, except during bathing.

Study summary

This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl auristatin E (MMAE) in patients with advanced cancers, including urothelial carcinoma. Eligible participants will have no baseline ≥ grade 1 neuropathy and will be scheduled to receive MMAE-containing ADC therapy. A total of 58 patients will be enrolled and followed for 24 months. In this self-controlled design, the left foot will be fitted with a medical compression stocking while the right foot remains uncovered, starting 15 minutes before infusion and continuing until 15 minutes after infusion (total duration: 120 minutes). Peripheral neuropathy will be assessed before treatment, after cycle 3, within 1 week after treatment completion, and 1 month after completion, using CTCAE v5.0 and patient-reported questionnaires (QLQ-C30 and FACT-GOG-NTx). Toe temperature will be measured to assess local microcirculation changes. The study will also monitor compression-related adverse events. The results will provide evidence for preventive strategies to reduce ADC-induced peripheral neuropathy and improve patients' quality of life.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years Histologically or cytologically confirmed advanced malignancy (including but not limited to urothelial carcinoma) eligible for MMAE-containing ADC therapy (e.g., EV, DV, BV) * ECOG performance status 0-2 * No baseline peripheral neuropathy ≥ Grade 1 (CTCAE v5.0) * Stable tumor status without other neurotoxic drugs in the past 2 months * Adequate organ function (blood counts, liver and kidney function) per protocol * Expected survival ≥ 3 months * Ability and willingness to comply with study procedures and provide written informed consent Exclusion Criteria: * Poor compliance or inability to follow protocol * Pre-existing peripheral neuropathy ≥ Grade 1 from prior platinum/taxane treatment * Severe diabetes or peripheral vascular disease * Neurological disorders causing nerve compression (e.g., carpal tunnel syndrome, radiculopathy) * Severe psychiatric conditions (depression, bipolar disorder, substance abuse) * Active uncontrolled infections requiring systemic antibiotics/antifungals/antivirals (≥ CTCAE Grade 2) * Active hepatitis or significant liver dysfunction not meeting inclusion criteria * Renal failure requiring dialysis * Immunodeficiency or history of organ transplantation * Severe nausea, headache, fatigue, or other debilitating symptoms * Active tuberculosis or uncontrolled pleural/pericardial effusion/ascites * Hypersensitivity to monoclonal antibodies or study device components * Participation in other clinical trials within 4 weeks * Known bleeding or coagulation disorders or receiving thrombolytic therapy * Any other condition judged by the investigator to preclude safe participation

Primary outcome measure(s)

Incidence of Grade ≥1 Peripheral Neuropathy (CTCAE v5.0) — Baseline (within 7 days before treatment start); At the end of Cycle 3 (each cycle = 28 days, within 7 days); At treatment completion (within 7 days of last ADC dose); 1 month (±7 days) after treatment completion.
The proportion of patients who develop Grade ≥1 peripheral neuropathy, as assessed by CTCAE version 5.0.

Trial sites (1)

Facility	City	Region	Status
Fudan University Shanghai Cancer Center	Shanghai	China	Recruiting

More Sheng Zhang trials in China

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies Recruiting

Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors Recruiting

Other trials for the same condition

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies Recruiting

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors Active, not recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors Active, not recruiting

Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy Recruiting

A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07164950 on ClinicalTrials.gov ↗ ← All trials in China